Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06360939
Other study ID # ETH02659
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 20, 2024
Est. completion date May 20, 2027

Study information

Verified date April 2024
Source Western Sydney Local Health District
Contact Saurabh Kumar, MBBS | PhD
Phone (02)88908140
Email saurabh.kumar@health.nsw.gov.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized clinical trial is to test the efficacy of stereotactic body radiation therapy (SBRT) in treating ventricular tachycardia (VT) in patients with advanced structural heart disease. The main questions it aims to answer are: - What is the efficacy of SBRT compared to catheter ablation (CA) in achieving a ≥ 75% reduction in VT burden at 6 months - What is the comparable safety profile of SBRT vs CA Researchers will compare SBRT and CA (standard of care).


Description:

Hypothesis We hypothesise that in an open label randomised controlled trial of patients with advanced structural heart disease and ventricular tachycardia (VT) that stereotactic body radiation therapy (SBRT) will be superior in reducing VT burden compared to standard care comprising of catheter ablation (CA) and routine medical care with acceptable safety and adverse events. Aims This is a trial to examine if in an open label randomised trial of 60 patients with structural heart disease and VT followed for 3 years with a minimum follow up of 1 year of SBRT compared CA results in: 1. An improvement in a primary outcome of proportion of patients with a ≥75% reduction in VT burden in the 6 months following intervention compared to the 6 months intervention 2. Comparable safety profile (serious adverse events [SAE] and adverse events of special interest [AESI] at 6 months; 3. reduction in secondary endpoints at 6, 12, 24 and 36 months of: any VT recurrence, absolute % reduction in VT burden compared to 6 months pre-treatment, number of anti-arrhythmic drugs (AADs) compared to pre-treatment, cardiovascular hospitalisation, all-cause mortality, cardiac transplantation, combined endpoint of cardiovascular hospitalisation/transplant/mortality, SAE and AESI from treatment, ventricular function abd change of quality of life (QOL) metrics (at 12 months).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date May 20, 2027
Est. primary completion date May 20, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Structural heart disease (including ischaemic cardiomyopathy , non-ischaemic cardiomyopathy or congenital heart disease and defined as any one of 1. segmental or global decreased ventricular wall motion as defined by TTE, CT or cMRI 2. myocardial hypertrophy 3. myocardial scar (evidenced by late gadolinium enhancement on cMRI, wall thinning on cardiac CT, low voltage on electrophysiological study or abnormal intracardiac echocardiography) 2. Recurrent monomorphic VT which can include 1. at least one episode of VT treated by ICD and/or 2. sustained VT (lasting >30s) and/or 3. inducible sustained VT on invasive electrophysiological study (EPS) or non-invasive programmed stimulation (NIPS) 3. PAINESD score of =9 points and/or at least moderate risk of VT recurrence or death as defined by the I-VT score. Both are validated tools used clinically to identify patient at high risk of VT recurrence and/or mortality after CA. Exclusion Criteria: 1. Age < 18 years 2. Life expectancy < 3 months 3. Catheter ablation deemed futile or with prohibitive risk by cardiac electrophysiologist. 4. Unwilling or unable to provide consent 5. Known cardiac channelopathies (e.g. Catecholaminergic polymorphic ventricular tachycardia (CPVT), long- or short QT syndrome, Brugada syndrome) 6. Contraindications to radiotherapy as deemed by referring physician and/or radiation oncologist 7. Pregnancy or breast feeding

Study Design


Intervention

Radiation:
SBRT
Delivery of 25Gy in a single dose fraction to target area within 6 weeks of randomization
Procedure:
CA
CA (endocardial and/or epicardial at operator discretion) within 6 weeks of randomization.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Western Sydney Local Health District National Heart Foundation, Australia, University of Sydney

Outcome

Type Measure Description Time frame Safety issue
Primary VT burden Change in proportion of patients with a =75% reduction in VT burden at 6 months (number of VT episodes in 6 months post treatment compared to the number of VT episodes in the 6 months prior to randomisation excluding a 6-week blanking period after treatment initiation) 6 months
Secondary Recurrent sustained VT Recurrent sustained VT ascertained by implanted cardioverter defibrillator (ICD) (VT identified and treated by the ICD with anti-tachycardia pacing (ATP) and/or internal ICD delivered shock or =30 seconds of VT if untreated by ICD 6, 12, 24 and 36 months
Secondary VT storm VT storm (three or more documented episodes of VT within 24 hours or incessant VT) 6, 12, 24 and 36 months
Secondary Absolute VT burden Absolute percentage reduction in VT burden compared to pre-ablation 6, 12, 24 and 36 months
Secondary Serious Adverse Events (SAE) and Adverse Events of Special Interest (AESI) SAE and AESI related to effects of SBRT
SAE and AESI related to standard care e.g. medical anti-arrhythmic drug therapy or catheter ablation or heart transplantation
At all time points up to 36 months
Secondary ICD shocks Implantable Cardioverter Defibrillator shocks 6, 12, 24 and 36 months
Secondary Hospitalization Cardiovascular as well as specifically heart failure and arrhythmia 6, 12, 24 and 36 months
Secondary All cause mortality All cause mortality 6,12, 24 and 36 months
Secondary Cardiovascular Mortality Cardiovascular mortality 6,12, 24 and 36 months
Secondary Composite outcome of VT recurrence/hospitalisation/death/ cardiac transplantation Composite outcome as above 6,12, 24 and 36 months
Secondary Ventricular function As determined by echocardiography (ejection fraction, speckle tracking echocardiography) 6,12, 24 and 36 months
Secondary Quality of Life as per Short Form - 36 (SF-36) Score Change in quality of life at 6 and 12 months (compared to pre-intervention) as measured by Short Form- 36 (SF-36) [0-100 scale, 0 is equivalent to maximum disability and a score of 100 is equivalent to no disability]. 6,12, 24 and 36 months
Secondary Quality of Life as per Implantable Cardioverter Defibrillator Concerns Questionnaire (ICDC) score Change in quality of life at 6 and 12 months (compared to pre-intervention) as measured by Implantable Cardioverter Defibrillator Concerns Questionnaire (ICDC) score. [0-100 scale, 100 equivalent to maximum concern] 6,12, 24 and 36 months
Secondary Number of AADs Number of AADs at time points following randomization 6,12, 24 and 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT03453645 - Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation
Completed NCT05791032 - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study N/A
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Completed NCT04011631 - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System. N/A
Recruiting NCT03536052 - Ablation at Virtual-hEart pRedicted Targets for VT N/A
Not yet recruiting NCT06063811 - Ventricular Tachycardia Ablation in LVAD Patients
Enrolling by invitation NCT02962076 - Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia Early Phase 1
Not yet recruiting NCT02784912 - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation N/A
Completed NCT01791543 - Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia N/A
Terminated NCT02891863 - Low Energy Therapy to Convert Ventricular Tachycardias Phase 0
Terminated NCT01546207 - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia N/A
Completed NCT01294267 - Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation N/A
Terminated NCT00383799 - Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia Phase 4
Completed NCT04884100 - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening N/A
Completed NCT04642963 - Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular Tachycardia N/A
Recruiting NCT05377216 - Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation Early Phase 1
Not yet recruiting NCT04990089 - VIVO European Observational Registry
Completed NCT04065893 - Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy
Recruiting NCT03631303 - Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias
Recruiting NCT03611465 - Creation of a Pace-mapping Atlas on Healthy and Pathological Hearts N/A